The continued success of efforts to reduce the global malaria burden will require sustained
funding for interventions specifically targeting Plasmodium vivax. The optimal use of limited …

In regions coendemic for P. vivax and P. falciparum, a unified treatment policy for malaria of
any parasitological cause is likely to confer the greatest individual and public health benefit …

Discussions beginning in 2012 ultimately led to a landmark document from the World Health
Organization (WHO) titled, Control and Elimination of Plasmodium vivax: A Technical Brief …

Plasmodium vivax malaria is a debilitating, sometimes life-threatening, and economically
repressive disease of many tropical and temperate countries outside Africa, and yet it is …

Objective To determine household and health-care provider costs associated with
Plasmodium vivax infection across a range of endemic settings. Methods We collected cost …

Plasmodium vivax threatens almost 40% of the world's population, resulting in 132-391
million clinical infections each year. Most of these cases originate from South East Asia and …

New diagnostics and treatment options for the radical cure of Plasmodium vivax malaria are
now available. At the 2019 annual meeting of the Vivax Working Group of the Asia Pacific …

Malaria is caused by multiple parasitic species of the genus Plasmodium. Although P.
falciparum accounts for the highest mortality, P. vivax is the most geographically dispersed …

There is inadequate understanding of the biology, pathology, transmission, and control of
Plasmodium vivax, the geographically most widespread cause of human malaria. During the …

Plasmodium vivax is the most widespread human malaria, putting 2.5 billion people at risk of
infection. Its unique biological and epidemiological characteristics pose challenges to …